Press Releases
Search
-
20 Dec 2022
CE-marking of VIDAS® KUBE™, the next generation system in the VIDAS® immunoassay portfolio
VIDAS® KUBE™ is the next generation automated immunoassay system for the renowned VIDAS® range. It will benefit clinical labs and food industries by providing results to help speed up patient care and protect consumers.
-
15 Dec 2022
2022 increased outlook and 2023 preview guidance
bioMérieux, a world leader in the field of in vitro diagnostics, today released its adjusted outlook for full-year 2022 and a preview of 2023 guidance.
-
16 Nov 2022
Survey bioMérieux OpinionWay - Antimicrobial Resistance and diagnostic tests
To mark World Antimicrobial Awareness Week organized by the WHO from November 18-24, bioMérieux presents the results of a bioMérieux/OpinionWay survey on the general public's knowledge of antimicrobial resistance and the use of diagnostic tests in France.
-
26 Oct 2022
Third-quarter 2022 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, releases its business review for the nine months ended September 30, 2022.
-
26 Sep 2022
New survey shows low adherence to guidelines in sepsis care puts patients at risk
To mark Sepsis Awareness Month, bioMérieux, a world leader in in vitro diagnostics with a long-standing commitment to the fight against sepsis, and the UK Sepsis Trust, an internationally renowned charity, have released new survey data of health professionals to assess their knowledge and practice in the management of sepsis. This survey was commissioned among 368 doctors across six European countries.
-
31 Aug 2022
First-Half 2022 Results
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 30 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2022.
-
22 Aug 2022
The SPECIFIC REVEAL® Rapid AST System has received Breakthrough Device Designation from the U.S. Food and Drug Administration
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that the U.S. Food and Drug Administration (FDA) has granted its Breakthrough Device Designation for the SPECIFIC REVEAL® Rapid Antimicrobial Susceptibility Test (AST) System.
-
28 Jul 2022
bioMérieux receives FDA Clearance for NEPHROCHECK® test on VIDAS®
bioMérieux announced the FDA Clearance of VIDAS® NEPHROCHECK® assay to detect kidney stress in patients at risk of acute kidney injury (AKI).
-
07 Jul 2022
bioMérieux launches 3P® ENTERPRISE, an innovative solution for the pharma industry
bioMérieux, a world leader in the field of in vitro diagnostics, launches 3P® ENTERPRISE, an innovative solution designed to ensure environmental monitoring processes are fully efficient and under control at all times.
-
06 Jul 2022
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, Evotec SE and bioMérieux announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).
-
19 May 2022
Closing of the acquisition of Specific Diagnostics
bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has finalized the acquisition of Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures.
-
13 May 2022
bioMérieux announces the CE marking of VIDAS® tests for Chikungunya virus diagnosis
bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE marking of its automated tests to diagnose Chikungunya virus (CHIKV) infection on immunoassay instruments of the VIDAS® range.
-
04 May 2022
bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® Joint Infection (JI) Panel has received De Novo authorization from the US Food and Drug Administration (FDA). This panel tests for 31 pathogens implicated in most acute joint infections, and also includes 8 antimicrobial resistance (AMR) genes.
-
12 Apr 2022
Specific Diagnostics acquisition
bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures.
-
11 Apr 2022
First-Quarter 2022 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2022.